Source-grounded facts extracted from Amylyx Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Amylyx Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, EPS $0.37 per share.
“Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, compared to net loss of $35.9 million, or $0.42 per share, for the same period in 2025.”
Amylyx Pharmaceuticals, Inc. completed an acquisition involving Eiger BioPharmaceuticals, Inc. for $35.1 million (closed 2024-07-09).
“the Company agreed to acquire substantially all of the Seller’s rights, title and interests in, to and under those assets and interests used by the Seller in the development, manufacture and commercialization of Avexitide for $35.1 million”
Amylyx Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.”
Amylyx Pharmaceuticals, Inc. announced a restructuring with charges of approximately $19 million affecting not specified (approximately 70%).
“Plan by the end of the third quarter of 2024. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $19 million. The Company is also evaluating its inventory purchase commitments and the impact its Restructuring Plan will have on inventory obsolescence. The Company may also incur other”
Bernhardt Zeiher was appointed as Class I Director at Amylyx Pharmaceuticals, Inc..
“On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director”
Amylyx Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $380.8 million, net income $49.3 million.
“• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter”
Amylyx Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $108.4 million, net income $4.7 million.
“• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter”
Amylyx Pharmaceuticals, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $102.7 million, net income $20.9 million, EPS $0.30 on a fully diluted per share basis.
“in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results ˗ Third quarter 2023 product revenue of $102.7 million; bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch ˗ Strong financial position supported by $20.9 million of net income during the”
Amylyx Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $98.2 million, net income $22.1 million, EPS $0.31 on a fully diluted per share basis.
“in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZATM in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the”
Amylyx Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.
“The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Amylyx Pharmaceuticals, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.
“The stockholders of the Company elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 or until their successors have been duly elected and qualified or until their earlier resignation or removal.”
Amylyx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $71.4 million, net income $1.6 million, or $0.02 per share, EPS $0.02 per share.
“in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO ® in U.S. and ALBRIOZATM in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline”
Karen Firestone was appointed as Director at Amylyx Pharmaceuticals, Inc..
“appointed Karen Firestone to fill the vacancy on the Board as a Class I director, effective as of March 16, 2023”
Amylyx Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $21.9 million, net income $42.7 million, or $0.65 per share.
“For the three months ended December 31, 2022, net product revenue was $21.9 million”
Amylyx Pharmaceuticals, Inc. reported quarter ended September 30, 2022 results: revenue $0.3 million, net income $53.8 million, EPS $0.92 per share.
“Financial Results for the Third Quarter Ended September 30, 2022 For the quarter ended September 30, 2022, net product revenue was $0.3 million and cost of sales were $0.2 million. Both net product revenue and cost of sales during the period were attributable to sales of ALBRIOZA in Canada. There were no product revenues or cost of sales for the comparable period in 2021. Research and development expenses were $24.9 million for the quarter ended September 30, 2022, compared to $12.9 million for the quarter ended September 30, 2021. The increase was mainly driven by higher product manufacturing and development expenses in support of the global Phase 3 PHOENIX clinical trial and launch preparation activities for commercialization, as well as additional personnel-related expenses due to new headcount to support research and development efforts. Selling, general and administrative expenses were $29.9 million for the quarter ended September 30, 2022, compared to $10.4 million for the quarte”
Isaac Cheng resigned as Member of the Board of Directors at Amylyx Pharmaceuticals, Inc..
“On November 1, 2022, Isaac Cheng, MD, a member of the board of directors of Amylyx Pharmaceuticals, Inc. (the “Company”), submitted his resignation from the board of directors, effective as of close of business on November 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.